Danegaptide for primary percutaneous coronary intervention in acute myocardial infarction patients: a phase 2...

Area of Science:

• Cardiology
• Pharmacology

Background:

• Reperfusion therapy for ST-segment elevation myocardial infarction (STEMI) can cause additional myocardial damage, known as reperfusion injury.
• Gap junction modulating peptides, like danegaptide, have shown promise in animal models for reducing this injury.

Purpose of the Study:

• To evaluate the therapeutic potential of danegaptide in reducing myocardial damage and improving myocardial salvage in STEMI patients undergoing primary percutaneous coronary intervention.
• To assess the effect of danegaptide at two different dose levels on myocardial salvage, infarct size, and left ventricular ejection fraction.

Main Methods:

• A clinical proof-of-concept study involving 585 STEMI patients with specific criteria (TIMI flow 0-1, single vessel disease, ischemia time < 6 hours).
• Patients received primary percutaneous coronary intervention and were randomized to high-dose danegaptide, low-dose danegaptide, or placebo.
• Myocardial salvage was assessed using cardiac MRI at 3 months as the primary outcome.

Main Results:

• A total of 243 patients (79 high dose, 80 low dose, 84 placebo) were included in the per-protocol analysis.
• Danegaptide did not significantly improve the myocardial salvage index (63.9% high dose, 65.6% low dose, 66.7% control; P=0.40).
• No significant differences were observed in final infarct size or left ventricular ejection fraction between the danegaptide groups and the placebo group.

Conclusions:

• Administration of danegaptide in STEMI patients undergoing primary PCI did not lead to improved myocardial salvage.
• The study did not demonstrate a therapeutic benefit of danegaptide for reducing reperfusion injury in this patient population.